Long-term storage of lipid-like nanoparticles for mRNA delivery
Source abstract
Abstract
Lipid-like nanoparticles (LLNs) have been extensively explored for messenger RNA (mRNA) delivery in various biomedical applications. However, the long-term storage of these nanoparticles is still a challenge for their clinical translation. In this study, we investigated a series of conditions for the long-term storage of LLNs with encapsulation of mRNA. We evaluated the stability of LLNs with different concentrations of cryoprotectants (sucrose, trehalose or mannitol) under the conditions of freezing or lyophilization processes. Through in vitro and in vivo mRNA delivery studies, we identified the optimal storage condition, and found that the addition with 5% (w/v) sucrose or trehalose to LLNs could remain their mRNA delivery efficiency for at least three months in the liquid nitrogen storage condition.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Lipid Membrane Structure and Behavior · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (34)
Show source-provided references
1. Nanoscale platforms for messenger RNA delivery
2. Messenger RNA delivery for tissue engineering and regenerative medicine applications10.1089/ten.tea.2017.0444 ↗
3. Biomedical applications of mRNA nanomedicine10.1007/s12274-018-2146-1 ↗
4. Tools for translation: non-viral materials for therapeutic mRNA delivery10.1038/natrevmats.2017.56 ↗
5. Therapeutic mRNA delivery to leukocytes10.1016/j.jconrel.2019.05.032 ↗
6. Lipid polymer hybrid nanomaterials for mRNA delivery10.1007/s12195-018-0536-9 ↗
7. Zhao · 2019 · 119291
8. Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA10.1038/s41551-018-0284-0 ↗
9. Lipid nanoparticles for delivery of messenger RNA to the back of the eye10.1016/j.jconrel.2019.04.015 ↗
10. High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing10.1073/pnas.1811276115 ↗
11. Multifunctional triblock copolymers for intracellular messenger RNA delivery10.1016/j.biomaterials.2012.06.020 ↗
12. Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format10.1016/j.jconrel.2012.12.029 ↗
13. In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles10.1021/mp100390w ↗
14. Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy10.1038/mt.2012.250 ↗
15. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy10.1038/nature18300 ↗
16. An orthogonal array optimization of lipid-like nanoparticles for mRNA delivery in vivo10.1021/acs.nanolett.5b03528 ↗
17. Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast cancer10.1007/s12274-019-2308-9 ↗
18. Dendrimer‐based lipid nanoparticles deliver therapeutic FAH mRNA to normalize liver function and extend survival in a mouse model of hepatorenal tyrosinemia type I10.1002/adma.201805308 ↗
19. Achieving long-term stability of lipid nanoparticles: examining the effect of pH, temperature, and lyophilization10.2147/IJN.S123062 ↗
20. Effect of freezing rate on physical stability of lyophilized cationic liposomes10.1248/cpb.53.301 ↗
21. An overview of liposome lyophilization and its future potential10.1016/j.jconrel.2009.10.024 ↗
22. Short-and long-term stability study of lyophilized solid lipid nanoparticles for gene therapy10.1016/j.ejpb.2008.09.015 ↗
23. Recent advances and further challenges in lyophilization10.1016/j.ejpb.2013.05.019 ↗
24. Long-term stability of sterically stabilized liposomes by freezing and freeze-drying: effects of cryoprotectants on structure10.1016/j.ejps.2010.08.010 ↗
25. Preparation of redispersible liposomal dry powder using an ultrasonic spray freeze-drying technique for transdermal delivery of human epithelial growth factor
26. Physical stability of nonviral plasmid‐based therapeutics10.1002/(SICI)1520-6017(200003)89:3<289::AID-JPS1>3.0.CO;2-N ↗
27. Optimization of the lyophilization process for long-term stability of solid–lipid nanoparticles10.3109/03639045.2011.645835 ↗
28. Effect of cryoprotectants on the porosity and stability of insulin-loaded PLGA nanoparticles after freeze-drying10.4161/biom.23246 ↗
29. Understanding the freezing of biopharmaceuticals: first-principle modeling of the process and evaluation of its effect on product quality10.1002/jps.23642 ↗
30. Trehalose and anhydrobiosis in tardigrades–evidence for divergence in responses to dehydration10.1111/j.1742-4658.2007.06198.x ↗
31. Effect of cryoprotectants on the reconstitution of surfactant-free nanoparticles of poly (DL-lactide-co-glycolide)10.1080/02652040500162659 ↗
32. Cryoprotectants for freeze drying of drug nano‐suspensions: effect of freezing rate10.1002/jps.21786 ↗
33. The effect of annealing and cryoprotectants on the properties of vacuum-freeze dried starch nanoparticles10.1016/j.carbpol.2012.02.013 ↗
34. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms10.1038/mt.2010.85 ↗